Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.12
+0.06000.50%
Post-market: 12.170.0454+0.37%17:54 EDT
Volume:7.45M
Turnover:91.47M
Market Cap:1.70B
PE:-3.62
High:12.66
Open:11.98
Low:11.82
Close:12.06
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.74
T/O Rate:5.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.33
PE(LYR):-3.18

Loading ...

Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now?

Simply Wall St.
·
Yesterday

Cathie Wood’s ARK Investment buys 467K shares of Intellia Therapeutics today

TIPRANKS
·
Yesterday

Tracking Cathie Wood: Continuously increasing positions in gene-editing leader Intellia, reducing holdings in Brera Holdings

Options & Short Sell
·
Sep 11

Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today

TIPRANKS
·
Sep 10

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Sep 09

Intellia Therapeutics Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Wedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral Rating

MT Newswires Live
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Intellia Rises After FDA Grants Fast-Track Status to Its Treatment for Rare Disease

Reuters
·
Sep 08

Intellia Therapeutics Shares up 4.9% Premarket After FDA Accepts to Fast-Track Co's Treatment for a Rare Swelling Disorder

THOMSON REUTERS
·
Sep 08

Intellia Therapeutics announces FDA acceptance of lonvo-z BLA

TIPRANKS
·
Sep 08

Intellia Says FDA Accepts Lonvo-Z BLA for Hereditary Angioedema, Grants Priority Review

Reuters
·
Sep 08

Intellia Therapeutics, - FDA Accepts Bla for Lonvo-Z and Grants Priority Review with Pdufa Date March 10, 2027

THOMSON REUTERS
·
Sep 08

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-Z) for Hereditary Angioedema (Hae)

THOMSON REUTERS
·
Sep 08

Intellia Therapeutics, - FDA not Planning to Hold Advisory Committee for Lonvo-Z Application

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 08

Intellia Therapeutics Secures Major Non-Dilutive Loan Financing

TIPRANKS
·
Sep 05

Intellia Awards 163,100 RSUs to 41 New Employees Under Inducement Plan

Reuters
·
Sep 05

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 05